12:00 AM
Oct 07, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Halozyme, Roche sales and marketing update

Halozyme said it received a $10 million milestone payment from Roche triggered by the European launch of a subcutaneous formulation of Herceptin trastuzumab to treat HER2-positive breast cancer. Halozyme said the subcutaneous...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >